A new generation of companion diagnostics: Cobas BRAF, KRAS and EGFR mutation detection tests

Expert Review of Molecular Diagnostics

Volumn 14, Issue 5, 2014, Pages 517-524

  Angulo, Barbara ^a   Lopez Rios, Fernando ^a   Gonzalez, David ^b  

^a Hospital Universitario Sanchinarro Laboratorio de Dianas Terapeuticas Centro Integral Oncologico Clara   (Spain)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

BRAF mutations; Cobas 480; Colorectal cancer; Companion diagnostics; EGFR mutations; KRAS mutations; Malignant melanoma; Molecular pathology; Non small cell lung cancer

Indexed keywords

B RAF KINASE; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FORMALDEHYDE; K RAS PROTEIN; MONOCLONAL ANTIBODY; PARAFFIN; PROTEIN TYROSINE KINASE INHIBITOR; BRAF PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN; TUMOR MARKER;

ARTICLE; ASSAY; COLORECTAL CANCER; DIAGNOSTIC KIT; DNA EXTRACTION; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; HUMAN; IN VITRO STUDY; LIMIT OF DETECTION; LUNG NON SMALL CELL CANCER; MELANOMA; MOLECULAR PATHOLOGY; MUTANT; ONCOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PYROSEQUENCING; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY AND SPECIFICITY; DNA MUTATIONAL ANALYSIS; EARLY CANCER DIAGNOSIS; GENETICS; MUTATION; NEOPLASMS; PROCEDURES;

BIOMARKERS, TUMOR; DNA MUTATIONAL ANALYSIS; EARLY DETECTION OF CANCER; HUMANS; MUTATION; NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84901248831     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.2014.910120     Document Type: Article

References (50)

1. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344(11):783-92 (Pubitemid 32222155
2. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364(26):2507-16
3. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361(10):947-57
4. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359(17):1757-65
5. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62(1):10-29
6. UKCR. Skin cancer incidence statistics. 2013
7. Romano E, Schwartz GK, Chapman PB, et al. Treatment implications of the emerging molecular classification system for melanoma. Lancet Oncol 2011;12(9): 913-22
8. Flaherty KT, Hodi FS, Fisher DE. From genes to drugs: Targeted strategies for melanoma. Nat Rev Cancer 2012;12(5): 349-61
9. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005;353(20): 2135-47 (Pubitemid 41653105
10. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006; 24(26):4340-6 (Pubitemid 46630793
11. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417(6892):949-54 (Pubitemid 34716871
12. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012;380(9839):358-65
13. Long GV, Trefzer U, Davies MA, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): A multicentre, open-label, phase 2 trial. Lancet Oncol 2012;13(11):1087-95
14. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367(18):1694-703
15. Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008; 455(7216):1069-75
16. Pao W, Hutchinson KE. Chipping away at the lung cancer genome. Nat Med 2012; 18(3):349-51
17. Weir BA, Woo MS, Getz G, et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 2007;450(7171): 893-8 (Pubitemid 350231325
18. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448(7153):561-6 (Pubitemid 47206930
19. Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med 2012;18(3):378-81
20. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 2010;11(2):121-8
21. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13(3): 239-46
22. Linardou H, Dahabreh IJ, Bafaloukos D, et al. Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nat Rev Clin Oncol 2009;6(6):352-66
23. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:10-958-67
24. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 2013;8(7): 823-59
25. UKCR. Bowel cancer incidence statistics. 2013
26. Cancer Genome Atlas N. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487(7407): 330-7
27. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis. Lancet Oncol 2010;11(8):753-62
28. Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 2010;28(7):1254-61
29. Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009;27(12). 2091-6
30. Douillard JY, Oliner KS, Siena S, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369(11):1023-34
31. Mattocks CJ, Morris MA, Matthijs G, et al. A standardized framework for the validation and verification of clinical molecular genetic tests. Eur J Hum Genet 2010;18(12): 1276-88
32. Wistuba II, Gelovani JG, Jacoby JJ, et al. Methodological and practical challenges for personalized cancer therapies. Nat Rev Clin Oncol 2011;8(3):135-41
33. Conde E, Angulo B, Izquierdo E, et al. Lung adenocarcinoma in the era of targeted therapies: Histological classification, sample prioritization, and predictive biomarkers. Clin Transl Oncol 2013;15(7):503-8
34. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012;366(8):707-14
35. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363(9):809-19
36. Anderson S, Bloom KJ, Vallera DU, et al. Multisite analytic performance studies of a real-Time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin-embedded tissue specimens of malignant melanoma. Arch Pathol Lab Med 2012;136(11). 1385-91
37. Lopez-Rios F, Angulo B, Gomez B, et al. Comparison of testing methods for the detection of BRAF V600E mutations in malignant melanoma: Pre-Approval validation study of the companion diagnostic test for vemurafenib. PloS One 2013;8(1):e53733
38. Lade-Keller J, Romer KM, Guldberg P, et al. Evaluation of BRAF mutation testing methodologies in formalin-fixed, paraffin-embedded cutaneous melanomas. J Mol Diag 2013;15(1):70-80
39. Qu K, Pan Q, Zhang X, et al. Detection of BRAF V600 mutations in metastatic melanoma: Comparison of the Cobas 4800 and Sanger sequencing assays. J Mol Diag 2013;15(6):790-5
40. Lopez-Rios F, Angulo B, Gomez B, et al. Comparison of molecular testing methods for the detection of EGFR mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer. J Clin Pathol 2013;66(5):381-5
41. Wong AT, To RM, Wong CL, et al. Evaluation of 2 real-Time PCR assays for in vitro diagnostic use in the rapid and multiplex detection of EGFR gene mutations in NSCLC. Diagn Mol Pathol 2013;22(3):138-43
42. O'Donnell P, Ferguson J, Shyu J, et al. Analytic performance studies and clinical reproducibility of a real-Time PCR assay for the detection of epidermal growth factor receptor gene mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer. BMC Cancer 2013;13:210
43. Benlloch S, Botero ML, Beltran-Alamillo J, et al. Clinical validation of a PCR assay for the detection of EGFR mutations in non-small-cell lung cancer: Retrospective testing of specimens from the EURTAC Trial. PLoS One 2014 9(2):e89518
44. Lee S, Brophy VH, Cao J, et al. Analytical performance of a PCR assay for the detection of KRAS mutations (codons 12/ 13 and 61) in formalin-fixed paraffinembedded tissue samples of colorectal carcinoma. Virchows Arch 2012;460(2): 141-9
45. Gonzalez de Castro D, Angulo B, Gomez B, et al. A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens. Br J Cancer 2012;107(2):345-51
46. Harle A, Busser B, Rouyer M, et al. Comparison of COBAS 4800 KRAS, TaqMan PCR and high resolution melting PCR assays for the detection of KRAS somatic mutations in formalin-fixed paraffin embedded colorectal carcinomas. Virchows Arch 2013;462(3):329-35
47. Gonzalez de Castro D, Clarke PA, Al-Lazikani B, Workman P. Personalized cancer medicine: Molecular diagnostics, predictive biomarkers, and drug resistance. Clin Pharmacol Ther 2013;93(3):252-9
48. Workman P, de Bono J. Targeted therapeutics for cancer treatment: Major progress towards personalised molecular medicine. Curr Opin Pharmacol 2008;8(4): 359-62
49. Chin L, Andersen JN, Futreal PA. Cancer genomics: From discovery science to personalized medicine. Nat Med 2011; 17(3):297-303
50. McCormack RT, Armstrong J, Leonard D. Codevelopment of Genome-Based Therapeutics and Companion Diagnostics: Insights From an Institute of Medicine Roundtable. JAMA 2014. [Epub ahead to print]